



The relative strengths and weaknesses of Genomic Health INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Genomic Health INC compared to the market average is the variable Long Term Liabilities, increasing the Economic Capital Ratio by 159% points. The greatest weakness of Genomic Health INC is the variable Selling and Marketing Expense, reducing the Economic Capital Ratio by 110% points.

The company's Economic Capital Ratio, given in the ranking table, is 344%, being 215% points above the market average of 129%.

Input Variable	Value in 1000 USD
Assets, Current	148,520
Assets, Non-Current	15,541
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	59,669
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	38,338
Long Term Liabilities	0
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	-27
Other Expenses	49,135
Other Liabilities	0
Other Net Income	-572
Other Revenues	275,706
Property Plant and Equipment	21,860
Research And Development Expense	56,064
Selling and Marketing Expense	134,858

Output Variable	Value in 1000 USD
Assets	185,921
Liabilities	38,338
Expenses	299,726
Revenues	275,706
Stockholders Equity	147,583
Net Income	-24,592
Comprehensive Net Income	-24,619
Economic Capital Ratio	344%